Skye Bioscience Advances Nimacimab Trial as Cash Runway Narrows
Event summary
- Skye Bioscience initiated Cohort 1 of its CBeyond Expansion Study for nimacimab, with a Cohort Review Committee meeting scheduled for May 18, 2026 to evaluate safety data.
- The company reported $17.1 million in cash and short-term investments as of March 31, 2026, sufficient to fund operations through Q4 2026 but excluding Phase 2b study costs.
- Skye completed compatibility studies with Halozyme’s ENHANZE technology for subcutaneous administration of nimacimab.
- Q1 2026 R&D expenses increased to $7.9 million from $7.2 million in Q1 2025, driven by clinical trial and manufacturing costs.
The big picture
Skye Bioscience is advancing its nimacimab program with a focus on Phase 2b readiness, leveraging partnerships for drug delivery optimization. The company's financial runway highlights the need for strategic funding decisions as it navigates the capital-intensive Phase 2b trial phase. The obesity treatment market remains competitive, with nimacimab positioned as a potential complementary therapy to existing GLP-1 agonists.
What we're watching
- Trial Progression
- Whether Cohort 2 enrollment will proceed as planned following the May 18 safety review, and the implications for Phase 2b readiness.
- Financial Sustainability
- The pace at which Skye will need to secure additional funding to support Phase 2b clinical costs and manufacturing scale-up.
- Regulatory Strategy
- How FDA feedback will shape the final Phase 2b trial design, particularly around dose selection and patient population targeting.
Related topics